
    
      Patients with PCOS diagnosis and that are able to attempt the inclusion criteria are divided
      in two groups: administration of metformin 500 mg tablet three times/day as well 1500 mg/day
      (group A)and administration of metformin 500 mg tablet twice/day or 1000 mg/day (group B).
      Blood samples were collected to the pharmacokinetic evaluation from first day of
      administration until 3 months after beginning of treatment. The patients are monitored during
      3 months and all side effects are register. The efficacy of both treatment are analyzed by
      biochemical and physical evaluation.
    
  